| Tizanidine | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | |
| Tizanidine | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | |
| Tizanidine | hsa00830 | Retinol metabolism | 4.25E-02 | 1 | P00325 | ADH1B | More | |
| Tizanidine | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | |
| Tizanidine | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | |
| Tizanidine | hsa01523 | Antifolate resistance | 1.68E-02 | 2 | Q92820, P04818 | GGH, TYMS | More | |
| Tizanidine | hsa03013 | RNA transport | 4.49E-02 | 5 | P62826, Q9UBU9, P63279, P68104, Q14232 | RAN, NXF1, UBE2I, EEF1A1, EIF2B1 | More | |
| Tizanidine | hsa03015 | mRNA surveillance pathway | 1.83E-02 | 3 | Q13362, Q14738, Q9UBU9 | PPP2R5C, PPP2R5D, NXF1 | More | |
| Tizanidine | hsa03020 | RNA polymerase | 6.21E-04 | 4 | P30876, P24928, P62487, Q9Y535 | POLR2B, POLR2A, POLR2G, POLR3H | More | |
| Tizanidine | hsa04020 | Calcium signaling pathway | 4.83E-02 | 4 | Q08828, P0DP23, P05141, P51828 | ADCY1, CALM1, SLC25A5, ADCY7 | More | |
| Tizanidine | hsa04022 | cGMP-PKG signaling pathway | 4.38E-03 | 6 | P18848, P31751, Q08828, P51828, P05141, P0DP23 | ATF4, AKT2, ADCY1, ADCY7, SLC25A5, CALM1 | More | |
| Tizanidine | hsa04024 | cAMP signaling pathway | 3.94E-02 | 4 | Q08828, P51828, P31751, P0DP23 | ADCY1, ADCY7, AKT2, CALM1 | More | |
| Tizanidine | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 4.54E-02 | 2 | Q8NHW4, Q13651 | CCL4L2, IL10RA | More | |
| Tizanidine | hsa04064 | NF-kappa B signaling pathway | 4.10E-03 | 4 | P01584, P63279, Q8NHW4, Q9NQC7 | IL1B, UBE2I, CCL4L2, CYLD | More | |
| Tizanidine | hsa04070 | Phosphatidylinositol signaling system | 9.86E-03 | 4 | P0DP23, O14986, Q16760, P48426 | CALM1, PIP5K1B, DGKD, PIP4K2A | More | |
| Tizanidine | hsa04071 | Sphingolipid signaling pathway | 1.19E-02 | 4 | P21453, Q9H228, P01375, Q13362 | S1PR1, EDG8, TNF, PPP2R5C | More | |
| Tizanidine | hsa04072 | Phospholipase D signaling pathway | 2.40E-03 | 6 | P31751, O14986, Q15438, Q08828, P51828, Q16760 | AKT2, PIP5K1B, PSCD1, ADCY1, ADCY7, DGKD | More | |
| Tizanidine | hsa04080 | Neuroactive ligand-receptor interaction | 1.97E-02 | 5 | P28472, P21453, Q9H228, P21730, P07550 | GABRB3, S1PR1, EDG8, C5AR1, ADRB2 | More | |
| Tizanidine | hsa04110 | Cell cycle | 6.63E-04 | 6 | P06493, O60566, P30304, P33981, P42773, P01106 | CDK1, BUB1B, CDC25A, TTK, CDKN2C, MYC | More | |
| Tizanidine | hsa04114 | Oocyte meiosis | 1.36E-03 | 5 | P0DP23, Q08828, P51828, Q13362, Q14738 | CALM1, ADCY1, ADCY7, PPP2R5C, PPP2R5D | More | |
| Tizanidine | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | |
| Tizanidine | hsa04140 | Autophagy - animal | 1.71E-02 | 5 | P31751, Q7L523, O75460, Q96GC9, Q8TEV9 | AKT2, RRAGA, ERN1, TMEM49, SMCR8 | More | |
| Tizanidine | hsa04152 | AMPK signaling pathway | 1.83E-02 | 3 | Q96RR4, Q13362, Q14738 | CAMKK2, PPP2R5C, PPP2R5D | More | |
| Tizanidine | hsa04211 | Longevity regulating pathway | 1.88E-02 | 4 | P31751, Q08828, P51828, P18848 | AKT2, ADCY1, ADCY7, ATF4 | More | |
| Tizanidine | hsa04213 | Longevity regulating pathway - multiple species | 4.54E-02 | 3 | P31751, Q08828, P51828 | AKT2, ADCY1, ADCY7 | More | |
| Tizanidine | hsa04217 | Necroptosis | 2.34E-02 | 4 | P01375, P48023, Q14765, Q99878 | TNF, FASLG, STAT4, H2AC14 | More | |
| Tizanidine | hsa04261 | Adrenergic signaling in cardiomyocytes | 7.54E-06 | 9 | P07550, Q08828, P51828, P22694, P31751, P18848, Q13362, Q14738, P0DP23 | ADRB2, ADCY1, ADCY7, PRKACB, AKT2, ATF4, PPP2R5C, PPP2R5D, CALM1 | More | |
| Tizanidine | hsa04371 | Apelin signaling pathway | 3.94E-02 | 4 | P31751, Q08828, P51828, P0DP23 | AKT2, ADCY1, ADCY7, CALM1 | More | |
| Tizanidine | hsa04380 | Osteoclast differentiation | 1.88E-02 | 4 | Q9NQC7, P23458, P31751, P01584 | CYLD, JAK1, AKT2, IL1B | More | |
| Tizanidine | hsa04612 | Antigen processing and presentation | 1.07E-03 | 6 | Q14953, P26715, P26717, Q13241, P01732, P01375 | KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | |
| Tizanidine | hsa04620 | Toll-like receptor signaling pathway | 2.54E-03 | 3 | P01584, P31751, Q8NHW4 | IL1B, AKT2, CCL4L2 | More | |
| Tizanidine | hsa04623 | Cytosolic DNA-sensing pathway | 2.21E-04 | 3 | P01584, Q9Y535, Q8NHW4 | IL1B, POLR3H, CCL4L2 | More | |
| Tizanidine | hsa04625 | C-type lectin receptor signaling pathway | 9.86E-03 | 4 | P01584, Q9NQC7, P31751, P0DP23 | IL1B, CYLD, AKT2, CALM1 | More | |
| Tizanidine | hsa04630 | JAK-STAT signaling pathway | 4.54E-02 | 3 | P31751, P23458, Q13651 | AKT2, JAK1, IL10RA | More | |
| Tizanidine | hsa04640 | Hematopoietic cell lineage | 4.95E-02 | 3 | P01730, P06127, P09564 | CD4, CD5, CD7 | More | |
| Tizanidine | hsa04650 | Natural killer cell mediated cytotoxicity | 5.05E-04 | 7 | P01375, P20963, Q13241, P26718, P26717, Q14953, P26715 | TNF, CD247, KLRD1, KLRK1, KLRC2, KIR2DS5, KLRC1 | More | |
| Tizanidine | hsa04657 | IL-17 signaling pathway | 2.41E-02 | 4 | P19875, P14780, P80188, P01375 | CXCL2, MMP9, LCN2, TNF | More | |
| Tizanidine | hsa04668 | TNF signaling pathway | 3.55E-02 | 4 | P01375, P18848, P19875, P14780 | TNF, ATF4, CXCL2, MMP9 | More | |
| Tizanidine | hsa04713 | Circadian entrainment | 4.54E-02 | 3 | P0DP23, Q08828, P51828 | CALM1, ADCY1, ADCY7 | More | |
| Tizanidine | hsa04720 | Long-term potentiation | 4.54E-02 | 3 | P0DP23, P18848, Q08828 | CALM1, ATF4, ADCY1 | More | |
| Tizanidine | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | |
| Tizanidine | hsa04725 | Cholinergic synapse | 1.39E-02 | 4 | Q08828, P51828, P18848, P31751 | ADCY1, ADCY7, ATF4, AKT2 | More | |
| Tizanidine | hsa04728 | Dopaminergic synapse | 5.83E-04 | 5 | P31751, P18848, Q13362, Q14738, P0DP23 | AKT2, ATF4, PPP2R5C, PPP2R5D, CALM1 | More | |
| Tizanidine | hsa04740 | Olfactory transduction | 2.52E-02 | 1 | Q9H255 | OR51E2 | More | |
| Tizanidine | hsa04742 | Taste transduction | 1.01E-02 | 1 | P30939 | HTR1F | More | |
| Tizanidine | hsa04750 | Inflammatory mediator regulation of TRP channels | 9.86E-03 | 4 | P01584, Q08828, P51828, P0DP23 | IL1B, ADCY1, ADCY7, CALM1 | More | |
| Tizanidine | hsa04911 | Insulin secretion | 2.40E-02 | 3 | Q08828, P51828, P18848 | ADCY1, ADCY7, ATF4 | More | |
| Tizanidine | hsa04912 | GnRH signaling pathway | 1.39E-02 | 4 | Q08828, P51828, P18848, P0DP23 | ADCY1, ADCY7, ATF4, CALM1 | More | |
| Tizanidine | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | |
| Tizanidine | hsa04915 | Estrogen signaling pathway | 2.13E-02 | 5 | P18848, Q08828, P51828, P31751, P0DP23 | ATF4, ADCY1, ADCY7, AKT2, CALM1 | More | |
| Tizanidine | hsa04916 | Melanogenesis | 2.40E-02 | 3 | P0DP23, Q08828, P51828 | CALM1, ADCY1, ADCY7 | More | |
| Tizanidine | hsa04921 | Oxytocin signaling pathway | 3.13E-02 | 3 | P0DP23, Q96RR4, Q13469 | CALM1, CAMKK2, NFATC2 | More | |
| Tizanidine | hsa04923 | Regulation of lipolysis in adipocytes | 5.15E-03 | 3 | Q08828, P51828, P31751 | ADCY1, ADCY7, AKT2 | More | |
| Tizanidine | hsa04924 | Renin secretion | 4.04E-02 | 2 | P22694, P07550 | PRKACB, ADRB2 | More | |
| Tizanidine | hsa04925 | Aldosterone synthesis and secretion | 9.86E-03 | 4 | P18848, Q08828, P51828, P0DP23 | ATF4, ADCY1, ADCY7, CALM1 | More | |
| Tizanidine | hsa04926 | Relaxin signaling pathway | 1.56E-03 | 7 | P31751, P18848, P22694, P14780, Q08828, P51828, P30679 | AKT2, ATF4, PRKACB, MMP9, ADCY1, ADCY7, GNA15 | More | |
| Tizanidine | hsa04927 | Cortisol synthesis and secretion | 7.43E-04 | 4 | P18848, Q08828, P51828, P22694 | ATF4, ADCY1, ADCY7, PRKACB | More | |
| Tizanidine | hsa04932 | Non-alcoholic fatty liver disease | 5.87E-04 | 8 | P31751, P01375, P49841, P18848, P48023, O75460, P01584, O95298 | AKT2, TNF, GSK3B, ATF4, FASLG, ERN1, IL1B, NDUFC2 | More | |
| Tizanidine | hsa04934 | Cushing syndrome | 4.54E-02 | 3 | P18848, Q08828, P51828 | ATF4, ADCY1, ADCY7 | More | |
| Tizanidine | hsa04935 | Growth hormone synthesis, secretion and action | 1.88E-02 | 4 | Q08828, P51828, P18848, P31751 | ADCY1, ADCY7, ATF4, AKT2 | More | |
| Tizanidine | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
| Tizanidine | hsa04970 | Salivary secretion | 7.22E-04 | 6 | P07550, Q08828, P51828, P22694, P0DP23, P49913 | ADRB2, ADCY1, ADCY7, PRKACB, CALM1, CAMP | More | |
| Tizanidine | hsa04971 | Gastric acid secretion | 2.54E-03 | 4 | Q08828, P51828, P15311, P0DP23 | ADCY1, ADCY7, VIL2, CALM1 | More | |
| Tizanidine | hsa04976 | Bile secretion | 1.59E-02 | 3 | Q08828, P51828, Q14032 | ADCY1, ADCY7, BAAT | More | |
| Tizanidine | hsa04979 | Cholesterol metabolism | 1.61E-02 | 2 | P38571, P61916 | LIPA, NPC2 | More | |
| Tizanidine | hsa05010 | Alzheimer disease | 4.94E-03 | 9 | O95298, Q00535, O75460, P0DP23, P01584, P18848, P31751, P05141, P28070 | NDUFC2, CDK5, ERN1, CALM1, IL1B, ATF4, AKT2, SLC25A5, PSMB4 | More | |
| Tizanidine | hsa05016 | Huntington disease | 2.24E-02 | 7 | O95298, P24928, P30876, P62487, P05141, O75460, P28070 | NDUFC2, POLR2A, POLR2B, POLR2G, SLC25A5, ERN1, PSMB4 | More | |
| Tizanidine | hsa05017 | Spinocerebellar ataxia | 3.94E-02 | 4 | O75460, P31751, P28070, P05141 | ERN1, AKT2, PSMB4, SLC25A5 | More | |
| Tizanidine | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.67E-02 | 9 | O95298, Q8TEV9, O75460, P18848, P05141, Q00535, P01584, P0DP23, P28070 | NDUFC2, SMCR8, ERN1, ATF4, SLC25A5, CDK5, IL1B, CALM1, PSMB4 | More | |
| Tizanidine | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | |
| Tizanidine | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | |
| Tizanidine | hsa05144 | Malaria | 1.91E-02 | 3 | P01375, P35443, P26718 | TNF, THBS4, KLRK1 | More | |
| Tizanidine | hsa05146 | Amoebiasis | 2.41E-02 | 4 | P19875, P01375, P30679, P22694 | CXCL2, TNF, GNA15, PRKACB | More | |
| Tizanidine | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | |
| Tizanidine | hsa05163 | Human cytomegalovirus infection | 9.70E-05 | 9 | P31751, P0DP23, Q8NHW4, Q08828, P51828, P23458, P01584, Q13651, P18848 | AKT2, CALM1, CCL4L2, ADCY1, ADCY7, JAK1, IL1B, IL10RA, ATF4 | More | |
| Tizanidine | hsa05164 | Influenza A | 4.49E-02 | 5 | P31751, P01584, P23458, P05141, Q9UBU9 | AKT2, IL1B, JAK1, SLC25A5, NXF1 | More | |
| Tizanidine | hsa05166 | Human T-cell leukemia virus 1 infection | 3.90E-02 | 7 | P23458, P05141, P62826, Q08828, P51828, P18848, P31751 | JAK1, SLC25A5, RAN, ADCY1, ADCY7, ATF4, AKT2 | More | |
| Tizanidine | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 4.82E-02 | 3 | P23458, Q13469, P0DP23 | JAK1, NFATC2, CALM1 | More | |
| Tizanidine | hsa05205 | Proteoglycans in cancer | 3.68E-02 | 5 | P14780, P01375, P23588, Q13635, P22694 | MMP9, TNF, EIF4B, PTCH1, PRKACB | More | |
| Tizanidine | hsa05212 | Pancreatic cancer | 2.33E-03 | 3 | P31751, Q15311, P23458 | AKT2, RALBP1, JAK1 | More | |
| Tizanidine | hsa05231 | Choline metabolism in cancer | 3.38E-02 | 3 | P31751, Q16760, O14986 | AKT2, DGKD, PIP5K1B | More | |
| Tizanidine | hsa05321 | Inflammatory bowel disease | 1.91E-02 | 3 | P01375, Q14765, Q9UL17 | TNF, STAT4, TBX21 | More | |
| Tizanidine | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
| Tizanidine | hsa05332 | Graft-versus-host disease | 7.27E-04 | 4 | P48023, P01375, P26715, Q13241 | FASLG, TNF, KLRC1, KLRD1 | More | |
